The Miami Myeloma MRD 2021 Virtual Meeting will take place on October 13, 2021 at 9am EDT/2pm BST/3pm CEST. Organized by the Multiple Myeloma Research Foundation & Sylvester Comprehensive Cancer Center, the meeting will bring together leading experts in multiple myeloma who will discuss the use of measurable residual disease (MRD) in clinical and trial settings, furthering our understanding of recent advances in the disease, and encouraging interactive discussion.
VJHemOnc is pleased to be the official media partner for the meeting.
This event is intended for Healthcare Professionals only and registration is subject to approval. Please apply for registration below and you will get a confirmation by email.
Meeting Chairs: Ola Landgren (Co-Lead) USA, Daniel Auclair (Co-Lead) USA, Dickran Kazandjian, USA.
Find out what to look forward to at the meeting from Daniel Auclair:
Agenda (Eastern Time):
9:00AM – 9:10AM 1. Welcome and introduction (Ola Landgren)
9:10AM- 9:20AM 2. Biology of MRD (Francesco Maura)
3. New MRD technologies, focus on myeloma (Chair: Daniel Auclair)
9:20AM-9:30AM A) NGS-based MRD: Applications in Myeloma – Lanny Kirsch
9:30AM – 10:10AM B) Proteomics
i. MSKCC approach/Binding Site – Katie Thoren ii. UHN approach/EasyM – Suzanne Trudel iii. Mayo Clinic Approach/Mass-Fix – Angela Dispenzieri iv. Sylvester approach/Q-TOF – Lisa Reidy
10:10AM – 11:00AM C) Liquid biopsies
i. DFCI approach – Irene Ghobrial ii. UHN Approach – Trevor Pugh iii. Stanford approach – David Kurtz iv. Sylvester approach – David Coffey
11:00AM – 11:30AM D) Imaging
i. MRI – Jens Hillengass ii. Immuno-PET – Gary Ulaner iii. Imaging the tumor and the micro-environment – Peter Choyke
11:30AM – 12:00PM Panel discussion on topic
12:00PM – 12:05PM Break
12:05PM – 12:25PM Lunch (fireside chat with Nicole Gormley & Ola Landgren)
4. MRD in various trial settings, latest updates (Chair: Dickran Kazandjian)
12:25PM – 12:45PM A) Smoldering myeloma
i. PETHEMA trial – Marivi Mateos ii. NCI trial – Dickran Kazandjian
12:45PM – 2:00PM B) NDMM setting
i. GRIFFIN — Peter Voorhees ii. MASTER – Luciano Costa iii. Manhattan trial – Neha Korde iv. FORTE – Stefania Oliva v. IFM2009 update – Aurore Perrot vi. New CTN trial – Saad Usmani vii. New ADVANCE trial – Elisabet Manasanch viii. MRD – Pfizer experience – Ed Chan (PFE)
2:00PM – 2:20PM C) Maintenance setting
i. SWOG 1803 — Amrita Krishnan ii. MSKCC long-term lenalidomide maintenance – Benjamin Diamond
2:20PM – 2:50PM Panel Discussion: Current and future role of MRD in clinical trials?
2:50PM – 2:55PM Break
2:55PM – 3:25PM 5. MRD in daily practice: today and tomorrow
i. Univ Chicago – Benjamin Derman ii. UCSF – Nina Shah iii. Mayo Clinic, Scottsdale – Rafael Fonseca
3:25 PM –3:35PM 6. Brief summary, next steps, and adjourn (Ola Landgren)
This meeting has been supported by the following sponsors:
VJHemOnc is intended for Healthcare Professionals only
By choosing to continue, you are confirming that you are a healthcare professional
Please enter your details if you would like to receive the latest hemonc news and updates